Antidote, formerly TrialReach, is a digital health company on a mission to accelerate the breakthroughs of new treatments by bridging the gap between medical research and the people who need it.
Antidote brings together talented people with pharmaceutical, technology, business, and public health backgrounds to achieve an important mission.
Antidote was founded in 2010 and are based in the New York, NY, London, U.K and Carmel, IN.
Antidote uses precision recruitment to match the right patients with the right trials, striking the right balance between technology and human touch to deliver high-quality patient engagement. Antidote operates with a truly patient-centric approach, balancing technology with a human touch.
Antidote is backed by Merck Global Health Innovation Fund, LBO France, Amadeus Capital Partners, Smedvig Capital, Octopus Ventures and others. This brings Antidote's total funding to $52.1M to date.